Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.40 USD
-0.01 (-3.23%)
Updated Sep 24, 2024 03:55 PM ET
After-Market: $0.41 +0.01 (2.24%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 1 - 20 ( 146 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
EHA ''24 Presentation Further Raises Tuspetinib''s Visibility Ahead of Triplet Combo Study Start
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Redefining the StaTUS Quo; KOL Survey Underscores Tuspetinib''s Potential in 1L r/r AML; PT Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Tuspetinib Continues to Advance in the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Incremental Tuspetinib Update at ASH as APTIVATE Enrollment Strong
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Clinical Profile Continues to Build in APTIVATE; Data Updated Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Building Numbers, Durability and Next Steps; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We See Important Tipping Point Coming After Long Path; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Encouraging Early APTIVATE Results; Expanded Tuspetinib Data Expected at ESH in October
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tusp Clinical Highlights Forge an Encouraging Trail; Split-Adjusted Target to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Preliminary Phase 1/2 APTIVATE Data Expected in Mid-2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; APTIVATE Gains Momentum With Data Updates Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tuspetinib Keeps Accumulating Responses in AML Population; Phase 1/2 APTIVATE Trial Progressing as Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tuspetinib ASH Data Prompt Broad Development Program in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
New and Improved G3 Formulation Begins Dosing in Phase 1a/b Trial of r/r AML Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Completion of Phase 1/2 Study Paves the Way For Tuspetinib''s Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; HM43239 Exhibits Preliminary Efficacy in r/r AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
HM43239 Yields Another CR; Expansion Trials in 2H22; Luxeptinib G3 Delivering Anticipated PK Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Dual Kinase Inhibitor Portfolio Remains in Strong Position; Next Updates at EHA and KOL Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; HM43239 Takes Center Stage; Updates Expected at EHA ''22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J